Skip to main content
Moberg Pharma logo

Moberg Pharma — Investor Relations & Filings

Ticker · MOB ISIN · SE0020353928 LEI · 549300XFXK7DVGDRP410 ST Manufacturing
Open in API
Filings indexed 785 across all filing types
Latest filing 2024-10-10 Major Shareholding Noti…
Country SE Sweden
Listing ST MOB

About Moberg Pharma

https://www.mobergpharma.com/

Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for Moberg Pharma AB (publ), specifically reporting that Avanza Bank Holding AB's subsidiary's holding has dropped below a threshold (5%). The table explicitly lists 'Reason for major shareholding notification Sell' and provides the 'Before' and 'After the transaction' share quantities and percentages. This structure perfectly matches the definition of a Major Shareholding Notification, which is classified as 'MRQ' (Major Shareholding Notification). The document is a direct notification of a change in ownership percentage, not a general regulatory filing (RNS) or a report itself.
2024-10-10 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding where Avanza Bank Holding AB has crossed a 5% ownership threshold in Moberg Pharma AB. This is a classic major shareholding notification, which corresponds to the 'Major Shareholding Notification' category.
2024-10-01 Swedish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding, specifically a 'Sell' transaction by a holder ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension') in Moberg Pharma AB (publ). It explicitly states the 'Reason for major shareholding notification' and provides the resulting distribution of total holdings, including the new percentage (4.99787%) and share count (2,392,974). This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2024-09-27 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding for Moberg Pharma AB, where Avanza Bank Holding AB reports crossing a 5% threshold due to the return of loaned shares. This is a standard major shareholding notification, which corresponds to the 'Major Shareholding Notification' category.
2024-09-24 Swedish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in Moberg Pharma AB. It explicitly mentions 'Reason for major shareholding notification' and provides details on shares held, voting rights, and the resulting percentage, noting that a threshold (5%) was crossed/undershot. This structure is characteristic of a Major Shareholding Notification, which in the provided schema corresponds to the 'MRQ' code.
2024-09-18 English
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients
Earnings Release Classification · 95% confidence The document is a press release from Moberg Pharma regarding clinical trial results for their drug MOB-015. It details a negative update on a subset of clinical trial data, which is a significant regulatory disclosure affecting the company's outlook. While it mentions a conference call, the primary purpose is the disclosure of material information regarding clinical trial progress, which falls under the 'Regulatory Filings' (RNS) category as it is a mandatory disclosure under the EU Market Abuse Regulation. Q3 2024
2024-09-13 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.